- US-listed companies
- NEOGENOMICS INC
NEOGENOMICS INCNEO
Market cap
$1.8B
P/E ratio
| Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | |
| Clinical Services | - | - | - | - | - | - | - | 242 | 361 | 382 | 404 | 419 | 496 |
| Pharma Services | - | - | - | - | - | - | - | 35 | 48 | 62 | 80 | 91 | - |
| Advanced Diagnostics | - | - | - | - | - | - | - | - | - | - | - | - | 96 |
| Total net revenue | - | - | - | - | - | - | - | 277 | 409 | 444 | 484 | 510 | 592 |
| Clinical Services | - | - | - | - | - | - | - | - | - | - | - | - | 287 |
| Advanced Diagnostics | - | - | - | - | - | - | - | - | - | - | - | - | 60 |
| COST OF REVENUE | - | - | - | - | - | - | - | 149 | 212 | 259 | 297 | 322 | 347 |
| Clinical Services | - | - | - | - | - | - | - | - | - | - | - | - | 209 |
| Advanced Diagnostics | - | - | - | - | - | - | - | - | - | - | - | - | 36 |
| GROSS PROFIT | 19 | 27 | 32 | 41 | 44 | 110 | 120 | 127 | 197 | 186 | 187 | 188 | 245 |
| General and administrative | 13 | 16 | 17 | 24 | 34 | 76 | 89 | 85 | 128 | 144 | 221 | 243 | 243 |
| Research and development | - | 2 | 2 | 3 | 4 | 5 | 4 | 3 | 8 | 8 | 22 | 30 | 27 |
| Sales and marketing | 7 | 8 | 9 | 12 | 12 | 24 | 25 | 29 | 47 | 48 | 63 | 67 | 71 |
| Restructuring charges | - | - | - | - | - | - | - | - | - | - | - | 5 | 11 |
| Total operating expenses | 20 | 26 | 29 | 38 | 49 | 108 | 118 | 117 | 184 | 200 | 306 | 346 | 352 |
| LOSS FROM OPERATIONS | -0 | 1 | 3 | 2 | -6 | 3 | 2 | 10 | 13 | -14 | -119 | -158 | -108 |
| Interest Expense | 1 | 1 | 1 | - | 1 | - | - | - | 4 | 7 | 5 | 2 | 7 |
| Interest income | - | - | - | - | - | - | - | - | - | - | - | - | 17 |
| Other expense (income), net | - | - | - | - | 2 | - | -0 | 0 | -5 | 12 | -0 | -0 | 1 |
| Interest expense | 1 | 1 | 1 | - | 1 | - | - | - | 4 | 7 | 5 | 2 | 7 |
| Other expense (income), net | - | - | - | - | 2 | - | -0 | 0 | -5 | 12 | -0 | -0 | 1 |
| Loss on extinguishment of debt | - | - | - | - | - | -1 | - | - | -1 | -1 | - | - | - |
| Gain on investment in and loan receivable from non-consolidated affiliate, net | - | - | - | - | - | - | - | - | - | - | 109 | - | - |
| Loss on termination of cash flow hedge | - | - | - | - | - | - | - | - | - | -4 | - | - | - |
| Loss before taxes | - | 0 | 2 | 1 | -4 | -7 | -3 | 4 | 4 | -14 | -15 | -159 | -97 |
| Loss before taxes | - | 0 | 2 | 1 | -4 | -7 | -3 | 4 | 4 | -14 | -15 | -159 | -97 |
| Income tax benefit | - | - | 0 | 0 | -2 | -2 | -3 | 1 | -4 | -18 | -7 | -15 | -9 |
| Income tax benefit | - | - | 0 | 0 | -2 | -2 | -3 | 1 | -4 | -18 | -7 | -15 | -9 |
| NET LOSS | -1 | 0 | 2 | 1 | -3 | -6 | -1 | 3 | 8 | 4 | -8 | -144 | -88 |
| NET LOSS | -1 | 0 | 2 | 1 | -3 | -6 | -1 | 3 | 8 | 4 | -8 | -144 | -88 |
| Basic (in dollars per share) | - | - | - | - | - | -0.39 | -0.14 | 0.07 | 0.08 | 0.04 | -0.07 | -1.16 | -0.7 |
| Diluted (in dollars per share) | - | - | - | - | - | -0.39 | -0.14 | 0.07 | 0.08 | 0.04 | -0.07 | -1.16 | -0.7 |
| Basic (in dollars per share) | - | - | - | - | - | -0.39 | -0.14 | 0.07 | 0.08 | 0.04 | -0.07 | -1.16 | -0.7 |
| Diluted (in dollars per share) | - | - | - | - | - | -0.39 | -0.14 | 0.07 | 0.08 | 0.04 | -0.07 | -1.16 | -0.7 |